

Bamlanivimab EUA for COVID-19

The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization.

Eligible Patients Considered High Risk*
<p>Patients with ≥ 1 of the following:</p> <ul style="list-style-type: none">• BMI ≥ 35• Chronic kidney disease• Diabetes• Immunosuppressive disease• Currently receiving immunosuppressive treatment• ≥ 65 years old <p>Patients ≥ 55 Years Old and ≥ 1 of the Following:</p> <ul style="list-style-type: none">• Cardiovascular disease• Hypertension• COPD or other chronic respiratory disease <p>Patients 12-17 Years Old and ≥ 1 of the Following:</p> <ul style="list-style-type: none">• BMI ≥ 85th percentile for their age and gender**• Sickle cell disease• Congenital or acquired heart disease• Neurodevelopmental disorders (i.e., cerebral palsy)• A medical-related technological dependence (i.e., tracheostomy, gastrostomy or positive pressure ventilation not related to COVID-19)• Asthma, reactive airway or other chronic respiratory disease that requires daily treatment <p>*Patients ≥ 12 years old who weight ≥ 40 kg with ≥ 1 of the criteria listed are considered at high risk for progressing to severe COVID-19 and/or hospitalization. FDA fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab available at: https://www.fda.gov/media/143603/download</p> <p>**Based on CDC growth charts (https://www.cdc.gov/growthcharts/clinical_charts.htm).</p> <p>Abbreviations: BMI – body mass index; COPD – chronic obstructive pulmonary disease</p>

The drug needs to be infused over 1 hour in a facility equipped to manage anaphylaxis. Bamlanivimab has not been beneficial in hospitalized patients.

https://jamanetwork.com/journals/jama/fullarticle/2774326?guestAccessKey=d6e0ca69-2f0f-4810-8a20-9eca565217cd&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_term=mostread&utm_content=olf-widget_12162020 - December 11, 2020

This work is licensed under the Creative Commons Attribution-NoDerivatives 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nd/4.0/>

This policy and procedure is not intended to replace the informed judgment of individual physicians, nurses or other clinicians nor is it intended as a statement of prevailing community standards or minimum standards of practice. It is a suggested method and technique for achieving optimal health care, not a minimum standard below which residents necessarily would be placed at risk.